These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 18786301

  • 1. Estimating the potential savings with vagus nerve stimulation for treatment-resistant depression: a payer perspective.
    Cohen LJ, Allen JC.
    Curr Med Res Opin; 2008 Aug; 24(8):2203-17. PubMed ID: 18786301
    [Abstract] [Full Text] [Related]

  • 2. Introduction of vagus nerve stimulation into a maintenance electroconvulsive therapy regimen: a case study and cost analysis.
    Warnell RL, Elahi N.
    J ECT; 2007 Jun; 23(2):114-9. PubMed ID: 17548984
    [Abstract] [Full Text] [Related]

  • 3. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M, Schein J, Mody S, Grant R, Benson C, Olson W.
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [Abstract] [Full Text] [Related]

  • 4. Payer cost savings with endometrial ablation therapy.
    London R, Holzman M, Rubin D, Moffitt B.
    Am J Manag Care; 1999 Jul; 5(7):889-97. PubMed ID: 10557409
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy.
    Helmers SL, Duh MS, Guérin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.
    Eur J Paediatr Neurol; 2012 Sep; 16(5):449-58. PubMed ID: 22261080
    [Abstract] [Full Text] [Related]

  • 6. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression.
    Feldman RL, Dunner DL, Muller JS, Stone DA.
    J Med Econ; 2013 Sep; 16(1):62-74. PubMed ID: 22954061
    [Abstract] [Full Text] [Related]

  • 7. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients.
    Ben-Menachem E, Hellström K, Verstappen D.
    Neurology; 2002 Sep 24; 59(6 Suppl 4):S44-7. PubMed ID: 12270968
    [Abstract] [Full Text] [Related]

  • 8. Clinical issues in considering vagus nerve stimulation for treatment-resistant depression.
    Rush AJ, Siefert SE.
    Exp Neurol; 2009 Sep 24; 219(1):36-43. PubMed ID: 19397908
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D, Baingana F, Kim J.
    J Ment Health Policy Econ; 2008 Sep 24; 11(3):127-33. PubMed ID: 18806302
    [Abstract] [Full Text] [Related]

  • 10. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression.
    Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D.
    Biol Psychiatry; 2008 Sep 15; 64(6):455-60. PubMed ID: 18571625
    [Abstract] [Full Text] [Related]

  • 11. VNS and depression: current status and future directions.
    Walsh SP, Kling MA.
    Expert Rev Med Devices; 2004 Sep 15; 1(1):155-60. PubMed ID: 16293018
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Sep 15; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 13. Vagus nerve stimulation acutely alters food craving in adults with depression.
    Bodenlos JS, Kose S, Borckardt JJ, Nahas Z, Shaw D, O'Neil PM, George MS.
    Appetite; 2007 Mar 15; 48(2):145-53. PubMed ID: 17081655
    [Abstract] [Full Text] [Related]

  • 14. Clinical benefits and cost effectiveness of vagus nerve stimulation in a long-term treatment of patients with major depression.
    Sperling W, Reulbach U, Kornhuber J.
    Pharmacopsychiatry; 2009 May 15; 42(3):85-8. PubMed ID: 19452375
    [Abstract] [Full Text] [Related]

  • 15. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
    Boulanger L, Zhao Y, Foster TS, Fraser K, Bledsoe SL, Russell MW.
    Curr Med Res Opin; 2009 Jul 15; 25(7):1763-73. PubMed ID: 19505204
    [Abstract] [Full Text] [Related]

  • 16. Neurostimulation therapies for treatment resistant depression: a focus on vagus nerve stimulation and deep brain stimulation.
    Rizvi SJ, Donovan M, Giacobbe P, Placenza F, Rotzinger S, Kennedy SH.
    Int Rev Psychiatry; 2011 Oct 15; 23(5):424-36. PubMed ID: 22200132
    [Abstract] [Full Text] [Related]

  • 17. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.
    Joyce AT, Smith P, Khandker R, Melin JM, Singh A.
    J Rheumatol; 2009 Apr 15; 36(4):743-52. PubMed ID: 19228658
    [Abstract] [Full Text] [Related]

  • 18. Neurostimulation therapies in depression: a review of new modalities.
    Marangell LB, Martinez M, Jurdi RA, Zboyan H.
    Acta Psychiatr Scand; 2007 Sep 15; 116(3):174-81. PubMed ID: 17655558
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Vagus nerve stimulation therapy for treatment of drug-resistant epilepsy and depression.
    Shafique S, Dalsing MC.
    Perspect Vasc Surg Endovasc Ther; 2006 Dec 15; 18(4):323-7. PubMed ID: 17351201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.